Keynote II: Towards Personalization of HPV Related Oropharyngeal Carcinoma

The goal of this session is understand what is the current standard approach to treat HPV+ oropharyngeal cancer.  In this talk, the speaker discusses the various broad approaches to de-intensify treatment for this disease and give evidence why some of the approaches have not been successful.  The speaker ends by informing the audience the need to implement personalized approach in treating HPV+ oropharyngeal cancer in keeping with the importance of precision medicine in 2022.

Target Audience

This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.

 

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Identify the accepted standard of care for HPV+ oropharyngeal cancer.
  • Identify general de-escalation trials.
  • Describe the novel personalized approach for HPV+ oropharyngeal cancer.
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 Certificate of Attendance
    This activity was designated for 0.75 AMA PRA Category 1 Credit™.
Course opens: 
02/11/2022
Course expires: 
02/26/2025
Cost:
$0.00
Part of: 
2022 Multidisciplinary Head and Neck Cancers Symposium onDemand
Rating: 
0

Nancy Lee, MD, FASTRO is employed by Memorial Sloan Kettering Cancer Center and receives research grants from AstraZeneca, Merck and Pfizer and is on the advisory borad of Elsie, Merck, Merck Serono, Pfizer and Roche.

All relevant relationships have been mitigated.

 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

 

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 Certificate of Attendance
    This activity was designated for 0.75 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.